Synonym: N-[4-[(7-Chloro-2,3,4,5-tetrahydro-5-hydroxy-1H-1-benzazepin-1-yl)carbonyl]-3-methylphenyl]-2-methylbenzamide; OPC 41061
CAS Number: 150683-30-0
Empirical Formula (Hill Notation): C26H25ClN2O3
Molecular Weight: 448.94
MDL Number: MFCD09838782
Linear Formula: C26H25ClN2O3
Product Type: Chemical
| assay |
≥98% (HPLC) |
| color |
white to tan |
| form |
powder |
| InChI |
1S/C26H25ClN2O3/c1-16-6-3-4-7-20(16)25(31)28-19-10-11-21(17(2)14-19)26(32)29-13-5-8-24(30)22-15-18(27)9-12-23(22)29/h3-4,6-7,9-12,14-15,24,30H,5,8,13H2,1-2H3,(H,28,31) |
| InChI key |
GYHCTFXIZSNGJT-UHFFFAOYSA-N |
| originator |
Sanofi Aventis |
| Quality Level |
100  |
| SMILES string |
Cc1ccccc1C(=O)Nc2ccc(c(C)c2)C(=O)N3CCCC(O)c4cc(Cl)ccc34 |
| solubility |
DMSO: ≥15 mg/mL |
| storage temp. |
2-8°C |
| Application: |
Tolvaptan has been used as a V2-selective antagonist for studying its effect on hypertension in mice. |
| Biochem/physiol Actions: |
Tolvaptan (OPC 41061) is a potent, orally active non-peptide vasopressin V2 selective antagonist. IC50 = 3 nM at the rat V2 receptor; 29 times more selective for the V2 than for V1a. Tolvaptan has also been shown to inhibit the development of polycystic kidney disease in several animal models. |
| Features and Benefits: |
This compound was developed by Sanofi Aventis . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: |
5, 25 mg in glass bottle |
| Preparation Note: |
Tolvaptan is soluble in DMSO at a concentration that is greater than or equal to 15 mg/ml. |
| RIDADR |
NONH for all modes of transport |
| WGK Germany |
WGK 3 |
| Flash Point(F) |
Not applicable |
| Flash Point(C) |
Not applicable |
| Purity |
≥98% (HPLC) |
| Storage Temp. |
2-8°C |
| UNSPSC |
51111800 |
